Can Mounjaro Cause Blindness? Study Results and Absolute Risk

Key Takeaways

• The July 2024 Hathaway study examined semaglutide, not Mounjaro. Its 8.9% figure was a 36-month cumulative estimate in a selected diabetes group, not 8.9 events per 100,000 person-years.
• NAION is not reversible, occurs suddenly (typically overnight), and presents as painless vision loss in one eye; it affects roughly 10 in 100,000 people annually in the general population.
• Optic disc anatomy, diabetes, hypertension and sleep apnea affect the interpretation of eye-event data. The studies do not establish an individual risk solely from membership in one of these groups.
• No causation has been proven; the association could reflect shared risk factors between obesity, diabetes, and NAION rather than direct drug effect.

The short answer

Current observational studies do not prove that Mounjaro causes blindness. Semaglutide-only research, pooled semaglutide-or-tirzepatide analyses and direct tirzepatide comparisons answer different questions. The comparison below separates those designs rather than assigning a semaglutide finding to Mounjaro.

Table of contents

1. The 2024 study that triggered the question
2. What NAION is and why it causes permanent vision loss
3. The actual numbers: relative risk vs absolute risk
4. The biological mechanism question: how could GLP-1 drugs affect the optic nerve?
5. Who is actually at risk: the "disc at risk" anatomy
6. What most articles get wrong about this association
7. The monitoring protocol: what to watch and when to call
8. The decision tree: should you start, continue, or stop Mounjaro?
9. Other GLP-1 vision concerns: diabetic retinopathy and the semaglutide data
10. When the risk-benefit calculation changes
11. FAQ

The 2024 study that triggered the question

Hathaway et al., 2024, examined a neuro-ophthalmology referral registry containing 16,827 patients. The exposure was semaglutide; there was no tirzepatide arm. The reported figures describe selected groups, not the general population.

2024 semaglutide study: original outcomes

Population	Events, semaglutide versus comparison	36-month cumulative incidence	Hazard ratio (95% CI)
Type 2 diabetes	17 versus 6	8.9% versus 1.8%	4.28 (1.62-11.29)
Overweight or obesity	20 versus 3	6.7% versus 0.8%	7.64 (2.21-26.36)

Cumulative incidence, observed event counts and a hazard ratio are different measures. None of these rows supplies a Mounjaro incidence rate. The retrospective design cannot establish causation.

What NAION is and why it causes permanent vision loss

Non-arteritic anterior ischemic optic neuropathy (NAION) is a stroke of the optic nerve. Blood flow to the optic nerve head (the part of the nerve visible during an eye exam) is interrupted, causing nerve cells to die. The damage is immediate and irreversible.

The "non-arteritic" part distinguishes it from arteritic AION, which is caused by giant cell arteritis, an inflammatory disease. NAION has no inflammation. It's a vascular event.

Typical presentation:

• Sudden, painless vision loss in one eye
• Occurs overnight or upon waking (most patients notice it when they open their eyes in the morning)
• Vision loss ranges from a small blind spot to complete loss of vision in the affected eye
• The second eye is affected in 15% to 20% of patients within 5 years

There is no effective treatment. Optic nerve cells do not regenerate. Some patients experience minor spontaneous improvement in the first 6 months, but most vision loss is permanent.

NAION affects roughly 10 in 100,000 people per year in the general U.S. population, with incidence increasing sharply after age 50. It's the most common cause of sudden optic nerve-related vision loss in adults over 50.

The actual numbers: relative risk vs absolute risk

Later studies use different medication comparators

Source	Comparison and follow-up	NAION result
Wang et al., 2025	Semaglutide or tirzepatide versus other antidiabetic medications; 79,699 per matched group; two years	35 versus 19 events; HR 1.76 (95% CI 1.01-3.07)
2026 tirzepatide comparison	Tirzepatide versus non-GIP GLP-1 receptor agonists; 102,590 per matched group; 36-month analysis	HR 0.45 (95% CI 0.27-0.86)

For the 2025 pooled groups, 35 divided by 79,699 multiplied by 100 is 0.043915%; 19 divided by 79,699 multiplied by 100 is 0.023839%. Their observed difference is 0.020076 percentage points, or 2.007553 events per 10,000 people over the follow-up window. These are proportions, not annual rates or a causal excess attributable to tirzepatide.

The 2026 result uses another GLP-1 medication group as its comparator. A lower relative hazard against that group does not demonstrate zero risk. Different comparison groups can produce different associations without contradicting one another.

The biological mechanism question: how could GLP-1 drugs affect the optic nerve?

No proven mechanism exists. Three hypotheses are under investigation:

Hypothesis 1: Blood pressure effects. GLP-1 receptor agonists lower systolic blood pressure by an average of 2 to 5 mmHg (Sharma et al., Diabetes Care 2023). NAION is thought to occur when perfusion pressure to the optic nerve head drops below a critical threshold, typically at night when blood pressure naturally dips. If GLP-1 drugs lower nocturnal blood pressure further, they could tip vulnerable patients into ischemia.

The studies above do not establish a mechanism that turns a blood-pressure change into an individual NAION prediction. Absence of a reported signal in one trial is not equivalent to a dedicated trial of that eye outcome.

Hypothesis 2: Microvascular changes. GLP-1 receptors are expressed on vascular endothelial cells. Activation could theoretically alter microvascular tone or permeability in the optic nerve circulation. This is speculative; no direct evidence supports it.

Hypothesis 3: Shared risk factors (confounding). Patients prescribed GLP-1 drugs have obesity, diabetes, hypertension, and sleep apnea at higher rates than the general population. All four are independent NAION risk factors. The association could be entirely explained by confounding, meaning the drug is a marker for high-risk patients, not a cause.

The Hathaway study attempted to match controls for diabetes and obesity status, but matching is imperfect in retrospective data. Optic disc anatomy (the strongest NAION predictor) was not assessed.

Confounding is one possible explanation, not a settled conclusion about the most likely mechanism. The observational comparisons cannot determine the mechanism by themselves.

Who is actually at risk: the "disc at risk" anatomy

The single strongest predictor of NAION is optic disc anatomy, specifically a small or absent optic cup. This is called "disc at risk" in ophthalmology literature.

The optic disc is the spot where the optic nerve enters the back of the eye. Normally, the center of the disc has a small depression called the cup. The cup-to-disc ratio is typically 0.3 to 0.5 (the cup occupies 30% to 50% of the disc diameter).

In "disc at risk" anatomy, the cup is tiny or absent (cup-to-disc ratio less than 0.2). The nerve fibers are crowded in a smaller space, and the blood vessels that supply the nerve have less room to navigate. This crowding makes the nerve head more vulnerable to ischemia when perfusion pressure drops.

Roughly 20% to 30% of the population has disc at risk anatomy in at least one eye. It's visible on a dilated eye exam or optical coherence tomography (OCT) imaging.

Other established NAION risk factors:

• Age over 50
• Hypertension (especially nocturnal non-dipping pattern)
• Diabetes
• Obstructive sleep apnea
• Smoking
• Nocturnal hypotension (blood pressure dropping too low during sleep)
• Hypercoagulable states
• Use of phosphodiesterase-5 inhibitors (Viagra, Cialis) in susceptible individuals

If you have disc at risk anatomy plus two or more other risk factors, your baseline NAION risk is substantially higher than the general population, and the relative risk increase from a GLP-1 drug becomes more concerning in absolute terms.

What most articles get wrong about this association

Most coverage of the Hathaway study made two errors:

Error 1: Treating association as causation. Headlines like "Ozempic linked to blindness" imply the drug causes NAION. The study showed an association. Association does not equal causation, especially in observational data where confounding is likely. The patients taking GLP-1 drugs are systematically different from the general population in ways that independently increase NAION risk.

A proper interpretation: "Patients prescribed GLP-1 drugs experienced NAION at higher rates than matched controls, but whether the drug itself increases risk or whether the association reflects unmeasured confounders is unknown."

Error 2: Mixing measures. A hazard ratio cannot be multiplied by an unrelated population rate to create a measured Mounjaro risk. Match the medication, comparator, population and follow-up period before interpreting a number.

The event denominator and observation period matter. A referral-center cumulative estimate should not be rewritten as a nationwide annual incidence.

The monitoring protocol: what to watch and when to call

If you're taking Mounjaro or compounded tirzepatide, the following protocol balances vigilance with practicality:

Before starting treatment:

• Baseline dilated eye exam if you have diabetes, are over 50, or have other NAION risk factors (hypertension, sleep apnea, known optic disc abnormalities)
• The exam should include optic disc assessment and cup-to-disc ratio documentation
• If you have disc at risk anatomy, discuss the NAION signal with your prescriber before starting

During treatment:

• Be aware of NAION symptoms: sudden, painless vision loss in one eye, typically noticed upon waking
• No routine eye exams are required solely because you're taking a GLP-1 drug (unless you have diabetic retinopathy, which has separate monitoring guidelines)
• Annual eye exams are reasonable if you have diabetes or are over 50, per standard guidelines

When to call immediately (same day):

• Sudden vision loss in one eye
• New blind spot or dark area in your visual field
• Sudden blurry vision that doesn't clear with blinking
• Loss of color vision in one eye

When to call within 24 to 48 hours:

• Gradual vision changes over days to weeks (this is not NAION but could indicate diabetic retinopathy progression or other issues)
• New floaters or flashes of light (possible retinal detachment, unrelated to GLP-1 drugs but urgent)

NAION is a same-day emergency. The vision loss is permanent, but immediate evaluation is needed to rule out other treatable causes (retinal artery occlusion, retinal detachment, optic neuritis) and to assess the second eye's risk.

The decision tree: should you start, continue, or stop Mounjaro?

If you have NOT started Mounjaro yet:

• Low-risk scenario (age under 50, no diabetes, no hypertension, no sleep apnea, normal eye exams in the past): The selected studies do not establish an individual risk or treatment decision for this scenario.

• Moderate-risk scenario (age 50+, or diabetes, or hypertension, but no known disc at risk anatomy): Consider a baseline eye exam to assess optic disc anatomy. If normal cup-to-disc ratio, proceed. If disc at risk, weigh the NAION signal against the benefit you expect from treatment.

• High-risk scenario (known disc at risk anatomy, plus age 50+, plus diabetes or hypertension or sleep apnea): The absolute NAION risk is higher in your case. Discuss alternatives (semaglutide has a similar signal; non-GLP-1 options like phentermine-topiramate, naltrexone-bupropion, or bariatric surgery have no NAION association). If you proceed, document informed consent and establish a monitoring plan.

If you are currently taking Mounjaro:

• No vision symptoms, no high-risk features: Continue. The benefit of sustained weight loss and metabolic improvement outweighs the small absolute NAION risk for most patients.

• No vision symptoms, but high-risk features discovered after starting: Schedule an eye exam to assess disc anatomy. If disc at risk, have a risk-benefit conversation with your provider. Many patients in this category choose to continue with heightened awareness of symptoms.

• New vision symptoms: Stop the medication and seek same-day ophthalmology evaluation. Do not wait.

If you have already had NAION in one eye:

The selected studies do not decide treatment for a person with prior NAION or establish a tirzepatide-specific contraindication from that history. Discuss non-GLP-1 weight-loss options.

Other GLP-1 vision concerns: diabetic retinopathy and the semaglutide data

A separate vision concern emerged from the SUSTAIN-6 trial (Marso et al., New England Journal of Medicine 2016), which found a higher rate of diabetic retinopathy complications in semaglutide-treated patients compared to placebo (3.0% vs 1.8%, p = 0.02).

The mechanism was clear: rapid glucose reduction. Patients who entered the trial with poor glucose control (HbA1c over 9%) and then experienced rapid HbA1c drops (more than 2 percentage points in 3 months) had worsening retinopathy. This is a known phenomenon called "early worsening" and occurs with any rapid glucose-lowering intervention, including insulin.

The solution: slower titration in patients with pre-existing retinopathy. The FDA label for semaglutide includes a warning about retinopathy complications in patients with a history of diabetic retinopathy. The warning does not apply to patients without pre-existing retinopathy.

Tirzepatide trials (SURPASS-1 through SURPASS-5) did not show the same retinopathy signal, possibly because titration schedules were more gradual or because the patient populations differed.

The retinopathy concern is mechanistically distinct from NAION. Retinopathy is a microvascular complication of diabetes that worsens with rapid glucose changes. NAION is an acute vascular event affecting the optic nerve. They are separate issues.

When the risk-benefit calculation changes

A benefit-risk comparison must use evidence for the specific medication, indication and outcome. The eye-event studies above do not quantify cardiovascular, kidney or mortality benefits against NAION for an individual.

The calculation changes in three scenarios:

Scenario 1: You have already had NAION in one eye. The studies above do not quantify an additional tirzepatide risk for this scenario or establish a mandatory weight-loss pathway.

Scenario 2: You have disc at risk anatomy in both eyes, plus multiple other NAION risk factors, and the benefit you are getting from the medication is marginal. Example: You have lost 5% of body weight after 6 months on tirzepatide, you have frequent side effects, and your primary goal was cosmetic rather than metabolic. In this case, the small absolute NAION risk might outweigh the small benefit. Stopping is reasonable.

Scenario 3: New evidence emerges showing a causal mechanism or higher absolute risk. The evidence now includes multiple observational designs, with differing medications and comparators. Monitor FDA communications and discuss updates with your provider.

Observational cohort results alone do not determine a start, continuation or discontinuation decision for an individual.

FAQ

Can Mounjaro cause blindness?

A semaglutide study cannot establish that Mounjaro causes blindness. Later observational comparisons include tirzepatide but do not establish causation or a single risk figure applicable to every user.

What is NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) is a stroke of the optic nerve caused by interrupted blood flow. It causes sudden, painless vision loss in one eye, typically noticed upon waking. The damage is permanent and irreversible.

How common is NAION in people taking Mounjaro?

The 2024 semaglutide-only referral study does not answer this Mounjaro-specific incidence question. A pooled-drug event proportion is also different from a tirzepatide-only annual incidence.

Does Mounjaro cause diabetic retinopathy?

A categorical “no” is not supported by the comparisons above. Diabetic retinopathy and NAION are distinct outcomes; a finding about one does not settle the other. Trial populations and changes in glucose control also matter.

Should I get an eye exam before starting Mounjaro?

If you have diabetes, yes, per standard ADA guidelines. If you are over 50 or have other NAION risk factors (hypertension, sleep apnea, known optic nerve issues), a baseline exam to assess optic disc anatomy is reasonable. If you are young and healthy with no risk factors, routine screening is not necessary.

What are the symptoms of NAION?

Sudden, painless vision loss in one eye, often noticed upon waking. The vision loss can range from a small blind spot to complete loss of vision. There is no eye pain, redness, or other symptoms. It is a medical emergency requiring same-day evaluation.

Can NAION be reversed?

No. The optic nerve damage is permanent. Some patients experience minor spontaneous improvement in the first 6 months, but most vision loss persists. There is no proven treatment.

Should I stop Mounjaro if I am worried about NAION?

Not without discussing it with your provider. For most patients, the cardiovascular and metabolic benefits of the medication far outweigh the small absolute NAION risk. If you have high-risk features (disc at risk anatomy, prior NAION), a risk-benefit conversation is appropriate.

Is the NAION risk the same for all GLP-1 drugs?

No. The original Hathaway study did not compare tirzepatide with semaglutide. Findings from different medication groups cannot establish equal risk across an entire drug class.

What is "disc at risk" anatomy?

An optic disc with a very small or absent central cup (cup-to-disc ratio less than 0.2). The crowded nerve fibers are more vulnerable to ischemia. It is visible on a dilated eye exam and is the strongest predictor of NAION risk. About 20% to 30% of people have this anatomy.

Can I take Mounjaro if I have sleep apnea?

Yes, but sleep apnea is an independent NAION risk factor. If you have untreated sleep apnea, treating it (with CPAP or other interventions) reduces NAION risk and is recommended regardless of whether you take Mounjaro.

What should I do if I notice sudden vision changes on Mounjaro?

Stop the medication and seek same-day ophthalmology evaluation. Sudden vision loss is a medical emergency. Do not wait to see if it improves.

Are there alternatives to Mounjaro without NAION risk?

Non-GLP-1 weight-loss medications (phentermine-topiramate, naltrexone-bupropion, orlistat) have no known NAION association. Bariatric surgery also has no NAION signal. Discuss options with your provider if NAION risk is a concern.

Does compounded tirzepatide have the same NAION risk as brand-name Mounjaro?

Shared active-ingredient identity does not establish measured equality of NAION risk between compounded and branded preparations. The selected studies do not provide that formulation-specific comparison.

How long does the NAION risk last after stopping Mounjaro?

The selected studies do not determine a post-discontinuation NAION timeline. Drug clearance alone is not a measured duration of eye-event risk.

Related guides

• Does Semaglutide Cause Blindness? Understanding the NAION Signal and What It Means for Your Treatment
• Can Ozempic Cause Blindness? The NAION Signal, What the Data Actually Shows, and When to Worry
• Does Zepbound Cause Blindness? The NAION Signal, What the Data Actually Shows, and When to Worry
• Does Wegovy Cause Blindness? Understanding the NAION Signal and Who's Actually at Risk
• Does Tirzepatide Cause Blindness? The Complete Evidence on NAION Risk and GLP-1 Vision Safety
• Does Mounjaro Cause Blindness? Understanding NAION Risk and What the Data Actually Shows

Sources

1. Hathaway et al. Semaglutide and NAION, 2024, PMID 38958939.
2. Wang et al. Semaglutide or tirzepatide and optic nerve disorders, 2025, DOI 10.1001/jamanetworkopen.2025.26327.
3. Ocular outcomes with tirzepatide versus GLP-1 receptor agonists, 2026, PMID 41655764.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Viagra and Cialis are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.